Quizartinib
Quizartinib regimen extends OS for certain patients with acute myeloid leukemia
The addition of quizartinib to chemotherapy extended OS for certain adults with newly diagnosed acute myeloid leukemia, according to topline data released by the agent’s manufacturer.
Sorafenib maintenance therapy reduces risk for relapse, death in AML subset
Sorafenib maintenance therapy reduced the risk for relapse and death after hematopoietic stem cell transplantation among a subset of patients with acute myeloid leukemia, according to study results published in Journal of Clinical Oncology.
HSCT after quizartinib or chemotherapy extends OS in AML subset
ORLANDO — Hematopoietic stem cell transplantation after treatment with quizartinib or salvage chemotherapy extended survival among patients with FLT-internal tandem duplication-mutated relapsed or refractory acute myeloid leukemia, according to post-hoc analyses of the randomized QuANTUM-R study presented at TCT | Transplantation & Cellular Therapy Meetings.
Co-mutations may impact response to quizartinib for relapsed/refractory acute myeloid leukemia
ORLANDO — Quizartinib significantly prolonged survival compared with salvage chemotherapy among patients with relapsed or refractory acute myeloid leukemia and high FLT3-internal tandem duplication variant allele frequency, according to prospective results presented at ASH Annual Meeting and Exposition.
VIDEO: New targeted therapies for AML now available in practice
In this video, Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, discusses new options that have entered the market for acute myeloid leukemia, including new targeted agents and therapies.